Article Data

  • Views 1842
  • Dowloads 171

Original Research

Open Access

Gonadal suppression alters axillary steroid secretions in men, but does that affect olfactory social signaling?

  • Syed Imran Ali Shah1
  • Hannah C. P. Wilson1
  • Paul D. Abel1
  • Richard J. Wassersug2
  • Vít Třebický3,4
  • Jitka Třebická Fialová3,5
  • Caroline Allen6
  • Hans H. Adomat7
  • Robert H. Bell7
  • Emma S. Tomlinson Guns7
  • S. Craig Roberts8

1Department of Surgery & Cancer, Imperial College London, SW7 1 London, UK

2Department of Cellular & Physiological Sciences, University of British Columbia, Vancouver, BC V6T, Canada

3National Institute of Mental Health, 250 67 Klecany, Czech Republic

4Faculty of Physical Education and Sport, Charles University, 120 00 Prague, Czech Republic

5Faculty of Science, Charles University, 120 00 Prague, Czech Republic

6School of Psychology, Newcastle University, NE2 4 England, UK

7Vancouver Prostate Centre, Vancouver, BC V4C, Canada

8Division of Psychology, University of Stirling, FK9 4 Scotland, UK

DOI: 10.31083/jomh.2021.042 Vol.17,Issue 3,July 2021 pp.69-76

Submitted: 25 February 2021 Accepted: 22 March 2021

Published: 08 July 2021

*Corresponding Author(s): Syed Imran Ali Shah E-mail: s.shah10@alumni.imperial.ac.uk
*Corresponding Author(s): Richard J. Wassersug E-mail: richard.wassersug@ubc.ca

PDF (113.77 kB)

Abstract

Background and objective: Luteinizing hormone-releasing hormone agonists (LHRHa) suppress gonadal hormone production and are commonly used to treat prostate cancer (PC) in men and conditions ranging from uterine fibroids to estrogen-sensitive cancers in women. They are also used to delay sexual development in children considering gender reassignment or experiencing premature puberty. As chemically castrating agents, LHRHa may affect cutaneous steroid secretions, which, in turn, could alter body odor and influence the psycho-sexual dynamics between individuals. The objectives of the present study were to determine (1) if LHRHa indeed alter cutaneous skin secretions, and (2) whether this leads to perceivable changes in body odor.

Material and methods: Axillary skin secretions were collected on new cotton T-shirts worn by men undergoing androgen deprivation therapy with an LHRHa to treat PC (n = 10), both before starting the LHRHa and 3 months later. Healthy heterosexual university students (50 males, 50 females) were recruited to smell and rate the shirts for their masculinity, attractiveness, and intensity of odor. Liquid chromatography-mass spectrometry (LC-MS) was also used to analyze steroids extracted from the shirt samples.

Results: LC-MS showed a statistically significant decline in the concentration of the androgenic metabolites, androsterone and 5α-androstane-3,17-dione. This confirms that LHRHa drugs that suppress gonadal hormone production markedly reduce cutaneous secretion of androgenic metabolic intermediates in adult males. However, no differences in odor were detected in the ratings of the shirts by male, female, nor male and female raters combined for any of the three variables assessed. Possible reasons why the human sniffers failed to perceive a change in odor are explored.

Conclusion: Our data document that LHRHa alter steroid skin secretions in older men, but whether such changes alter the olfactory signals that might influence psychosocial interactions remains unresolved.

Keywords

Prostate cancer; Androgen deprivation therapy; Scent; Olfaction; Social implications

Cite and Share

Syed Imran Ali Shah,Hannah C. P. Wilson,Paul D. Abel,Richard J. Wassersug,Vít Třebický,Jitka Třebická Fialová,Caroline Allen,Hans H. Adomat,Robert H. Bell,Emma S. Tomlinson Guns,S. Craig Roberts. Gonadal suppression alters axillary steroid secretions in men, but does that affect olfactory social signaling?. Journal of Men's Health. 2021. 17(3);69-76.

References

[1] Thomas BC, Neal DE. Androgen deprivation treatment in prostate cancer. British Medical Journal. 2013; 346: e8555.

[2] Ahmadi H, Daneshmand S. Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes. Patient Related Outcome Measures. 2014; 5: 63–70.

[3] Bangalore Krishna K, Fuqua JS, Rogol A, Klein K, Popovic J, Houk C, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Hormone Research in Paediatrics. 2019; 91: 357–372.

[4] Shah SIA. Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer. South Asian Journal of Cancer. 2015; 4: 95–97.

[5] Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. Journal of the American Medical Association. 2005; 294: 239–244.

[6] Freedland SJ, Eastham J, Shore N. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer and Prostatic Diseases. 2009; 12: 333–338.

[7] Donovan KA, Walker LM, Wassersug RJ, Thompson LMA, Robinson JW. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer. 2015; 121: 4286–4299.

[8] Tsang VWL, Skead C, Wassersug RJ, Palmer-Hague JL. Impact of prostate cancer treatments on men’s understanding of their masculinity. Psychology of Men & Masculinities. 2019; 20: 214–225.

[9] Eisenegger C, Haushofer J, Fehr E. The role of testosterone in social interaction. Trends in Cognitive Sciences. 2011; 15: 263–271.

[10] Walker LM, Santos-Iglesias P, Robinson J. Mood, sexuality, and relational intimacy after starting androgen deprivation therapy: implications for couples. Supportive Care in Cancer. 2018; 26: 3835–3842.

[11] Wassersug RJ. Maintaining intimacy for prostate cancer patients on androgen deprivation therapy. Current Opinion in Supportive and Palliative Care. 2016; 10: 55–65.

[12] Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW, ADT Survivorship Working Group. Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. The Journal of Sexual Medicine. 2010; 7: 2996–3010.

[13] Navon L, Morag A. Advanced prostate cancer patients’ relationships with their spouses following hormonal therapy. European Journal of Oncology Nursing. 2003; 7: 73–80.

[14] Wyatt TD. The search for human pheromones: the lost decades and the necessity of returning to first principles. Proceedings. Biological Sciences. 2015; 282: 20142994.

[15] Gosling LM, Roberts SC. Scent-marking by male mammals: cheat-proof signals to competitors and mates. Advances in the Study of Behavior. 2001; 30: 169–217.

[16] Dandine-Roulland C, Laurent R, Dall’Ara I, Toupance B, Chaix R. Genomic evidence for MHC disassortative mating in humans. Proceedings of the Royal Society B: Biological Sciences. 2019; 286: 20182664.

[17] Havlíček J, Fialová J, Roberts SC. Individual variation in body odor. Springer Handbook of Odor. 2017; 28: 125–126.

[18] Prokop-Prigge KA, Greene K, Varallo L, Wysocki CJ, Preti G. The effect of ethnicity on human axillary odorant production. Journal of Chemical Ecology. 2016; 42: 33–39.

[19] Havlicek J, Murray AK, Saxton TK, Roberts SC. Current issues in the study of androstenes in human chemosignaling. Vitamins and Hormones. 2010; 83: 47–81.

[20] Saxton TK, Lyndon A, Little AC, Roberts SC. Evidence that an-drostadienone, a putative human chemosignal, modulates women’s attributions of men’s attractiveness. Hormones and Behavior. 2008; 54: 597–601.

[21] Havlicek J, Roberts SC, Flegr J. Women’s preference for dominant male odour: effects of menstrual cycle and relationship status. Biology Letters. 2005; 1: 256–259.

[22] Thornhill R, Chapman JF, Gangestad SW. Women’s preferences for men’s scents associated with testosterone and cortisol levels: Patterns across the ovulatory cycle. Evolution and Human Behavior. 2013; 34: 216–221.

[23] Mitro S, Gordon AR, Olsson MJ, Lundström JN. The smell of age: perception and discrimination of body odors of different ages. PLoS ONE. 2012; 7: e38110.

[24] Lobmaier JS, Fischbacher U, Wirthmüller U, Knoch D. The scent of attractiveness: levels of reproductive hormones explain individual differences in women’s body odour. Proceedings of the Royal Society B: Biological Sciences. 2018; 285: 20181520.

[25] Jacob S, Hayreh DJ, McClintock MK. Context-dependent effects of steroid chemosignals on human physiology and mood. Physiology & Behavior. 2001; 74: 15–27.

[26] Berglund H, Lindström P, Savic I. Brain response to putative pheromones in lesbian women. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103: 8269–8274.

[27] Verhaeghe J, Gheysen R, Enzlin P. Pheromones and their effect on women’s mood and sexuality. Facts, Views & Vision in ObGyn. 2013; 5: 189–195.

[28] Preti G, Wysocki CJ, Barnhart KT, Sondheimer SJ, Leyden JJ. Male axillary extracts contain pheromones that affect pulsatile secretion of luteinizing hormone and mood in women recipients. Biology of Reproduction. 2003; 68: 2107–2113.

[29] d’Ettorre P, Bueno S, Rödel HG, Megherbi H, Seigneuric A, Schaal B, et al. Exposure to androstenes influences processing of emotional words. Frontiers in Ecology and Evolution. 2018; 5: 169.

[30] Havlíček J, Lenochová P, Oberzaucher E, Grammer K, Roberts SC. Does length of sampling affect quality of body odor samples?Chemosensory Perception. 2011; 4: 186–194.

[31] Roberts SC, Gosling LM, Carter V, Petrie M. MHC-correlated odour preferences in humans and the use of oral contraceptives. Proceedings: Biological Sciences. 2008; 275: 2715–2722.

[32] Lenochova P, Roberts SC, Havlicek J. Methods of human body odor sampling: the effect of freezing. Chemical Senses. 2009; 34: 127–138.

[33] Martinec Nováková LM, Havlíček J, Roberts SC. Olfactory processing and odor specificity: a meta-analysis of menstrual cycle variation in olfactory sensitivity. Anthropological Review. 2014; 77: 331–345.

[34] Gordon JA, Noble JW, Midha A, Derakhshan F, Wang G, Adomat HH, et al. Upregulation of scavenger receptor B1 is required for steroido-genic and nonsteroidogenic cholesterol metabolism in prostate cancer. Cancer Research. 2019; 79: 3320–3331.

[35] Deb S, Pham S, Ming D, Chin MY, Adomat H, Hurtado-Coll A, et al. Characterization of precursor-dependent steroidogenesis in human prostate cancer models. Cancers. 2018; 10: 343.

[36] Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. The Journal of Investigative Dermatology. 2002; 119: 992–1007.

[37] Bird J, Li X, Lei ZM, Sanfilippo J, Yussman MA, Rao CV. Luteinizing hormone and human chorionic gonadotropin decrease type 2 5α-reductase and androgen receptor protein levels in women’s skin. The Journal of Clinical Endocrinology & Metabolism. 1998; 83: 1776–1782.

[38] Pandey SK, Kim K. Human body-odor components and their determi-nation. TrAC Trends in Analytical Chemistry. 2011; 30: 784–796.

[39] Haze S, Gozu Y, Nakamura S, Kohno Y, Sawano K, Ohta H, et al. 2-Nonenal newly found in human body odor tends to increase with aging. The Journal of Investigative Dermatology. 2001; 116: 520–524.

[40] Zhang X, Firestein S. Nose thyself: individuality in the human olfactory genome. Genome Biology. 2007; 8: 230.

[41] Hasin-Brumshtein Y, Lancet D, Olender T. Human olfaction: from genomic variation to phenotypic diversity. Trends in Genetics. 2009; 25: 178–184.

[42] Kohoutová D, Rubešová A, Havlíček J. Shaving of axillary hair has only a transient effect on perceived body odor pleasantness. Behavioral Ecology and Sociobiology. 2012; 66: 569–581.

[43] Xu Y, Dixon SJ, Brereton RG, Soini HA, Novotny MV, Trebesius K, et al. Comparison of human axillary odour profiles obtained by gas chromatography/mass spectrometry and skin microbial profiles obtained by denaturing gradient gel electrophoresis using multivariate pattern recognition. Metabolomics. 2007; 3: 427–437.

[44] Sterndorff EB, Russel J, Jakobsen J, Mortensen MS, Gori K, Herschend J, et al. The T-shirt microbiome is distinct between individuals and shaped by washing and fabric type. Environmental Research. 2020; 185: 109449.

[45] Rumsey N, Harcourt D. Oxford handbook of the psychology of appearance. Oxford University Press. New York, NY, US. 2012.

[46] Unger CA. Hormone therapy for transgender patients. Translational Andrology and Urology. 2016; 5: 877–884.

[47] Mahfouda S, Moore JK, Siafarikas A, Zepf FD, Lin A. Puberty suppression in transgender children and adolescents. The Lancet Diabetes & Endocrinology. 2017; 5: 816–826.

[48] Anacker C, Sydnor E, Chen BK, LaGamma CC, McGowan JC, Mastrodonato A, et al. Behavioral and neurobiological effects of GnRH agonist treatment in mice-potential implications for puberty suppression in transgender individuals. Neuropsychopharmacology. 2021; 46: 882-890.

[49] Frey JD, Poudrier G, Thomson JE, Hazen A. A Historical review of gender-affirming medicine: focus on genital reconstruction surgery. The Journal of Sexual Medicine. 2017; 14: 991-1002.

[50] Radix A. Hormone therapy for transgender adults. The Urologic Clinics of North America. 2019; 46: 467–473.

[51] Kranz GS, Kaufmann U, Lanzenberger R. Probing the impact of gender-affirming hormone treatment on odor perception. Chemical Senses. 2020; 45: 37–44.

Abstracted / indexed in

Science Citation Index Expanded Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Social Sciences Citation Index Social Sciences Citation Index contains over 3,400 journals across 58 social sciences disciplines, as well as selected items from 3,500 of the world’s leading scientific and technical journals. More than 9.37 million records and 122 million cited references date back from 1900 to present.

Current Contents - Social & Behavioral Sciences Current Contents - Social & Behavioral Sciences provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in the social and behavioral sciences.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

SCOPUS Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.

DOAJ DOAJ is a community-curated online directory that indexes and provides access to high quality, open access, peer-reviewed journals.

CrossRef Crossref makes research outputs easy to find, cite, link, assess, and reuse. Crossref committed to open scholarly infrastructure and collaboration, this is now announcing a very deliberate path.

Portico Portico is a community-supported preservation archive that safeguards access to e-journals, e-books, and digital collections. Our unique, trusted process ensures that the content we preserve will remain accessible and usable for researchers, scholars, and students in the future.

Submission Turnaround Time

Conferences

    Top